丰原药业
(000153)
| 流通市值：29.67亿 | | | 总市值：30.31亿 |
| 流通股本：4.55亿 | | | 总股本：4.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,261,422,843.25 | 2,307,876,468.11 | 1,120,669,012.93 | 4,275,436,713.72 |
| 营业收入 | 3,261,422,843.25 | 2,307,876,468.11 | 1,120,669,012.93 | 4,275,436,713.72 |
| 二、营业总成本 | 3,112,687,590.78 | 2,188,816,635.08 | 1,058,729,460.12 | 4,098,576,045.54 |
| 营业成本 | 2,525,865,523.95 | 1,768,934,954.47 | 832,638,871.03 | 3,176,289,092.04 |
| 税金及附加 | 26,103,971.1 | 17,729,270.56 | 9,186,753.28 | 37,578,507.96 |
| 销售费用 | 384,733,267.46 | 284,701,959.93 | 159,552,828.87 | 584,288,566.79 |
| 管理费用 | 114,105,171.23 | 76,776,982.48 | 37,790,162.18 | 197,610,576.03 |
| 研发费用 | 40,361,583.34 | 26,360,784.48 | 12,983,646.7 | 77,023,417.77 |
| 财务费用 | 21,518,073.7 | 14,312,683.16 | 6,577,198.06 | 25,785,884.95 |
| 其中:利息费用 | 23,037,925.31 | 15,015,703.81 | 6,928,471.53 | 33,894,396.79 |
| 其中:利息收入 | 1,904,128.83 | 914,211.45 | 631,800.04 | 8,710,670.66 |
| 加:公允价值变动收益 | -9,916,334.26 | -18,160,043.69 | -10,444,151.2 | -6,920,724.85 |
| 加:投资收益 | 9,902,752.75 | 4,009,134.25 | - | 5,342,262.43 |
| 资产处置收益 | -1,135,848.39 | -1,135,848.39 | - | 4,381,091.55 |
| 资产减值损失(新) | -1,279,211.87 | -1,305,840.82 | -1,341,208.31 | -8,335,909.67 |
| 信用减值损失(新) | -4,563,621.79 | -3,555,321.76 | -2,339,521.95 | 2,492,206.6 |
| 其他收益 | 41,454,662.17 | 35,808,574.79 | 18,765,531.63 | 39,433,999.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 183,197,651.08 | 134,720,487.41 | 66,580,202.98 | 213,253,593.94 |
| 加:营业外收入 | 2,964,679.37 | 872,021.54 | 380,251.91 | 3,143,775.1 |
| 减:营业外支出 | 279,359.74 | 47,224.6 | 176,869.56 | 1,504,805.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 185,882,970.71 | 135,545,284.35 | 66,783,585.33 | 214,892,563.09 |
| 减:所得税费用 | 40,791,878.17 | 36,767,346.95 | 20,420,044.17 | 57,595,861.3 |
| 六、净利润 | 145,091,092.54 | 98,777,937.4 | 46,363,541.16 | 157,296,701.79 |
| 持续经营净利润 | 145,091,092.54 | 98,777,937.4 | 46,363,541.16 | 157,296,701.79 |
| 归属于母公司股东的净利润 | 147,302,850.89 | 100,212,492.64 | 47,010,852.21 | 159,285,567.9 |
| 少数股东损益 | -2,211,758.35 | -1,434,555.24 | -647,311.05 | -1,988,866.11 |
| (一)基本每股收益 | 0.32 | 0.22 | 0.14 | 0.48 |
| (二)稀释每股收益 | 0.32 | 0.22 | 0.14 | 0.48 |
| 八、其他综合收益 | -808,596.84 | 1,745,139.81 | -92,681.15 | -1,846,777.03 |
| 归属于母公司股东的其他综合收益 | -963,258.21 | 1,607,776.64 | -174,632.28 | -2,077,877.7 |
| 九、综合收益总额 | 144,282,495.7 | 100,523,077.21 | 46,270,860.01 | 155,449,924.76 |
| 归属于母公司股东的综合收益总额 | 146,339,592.68 | 101,820,269.28 | 46,836,219.93 | 157,207,690.2 |
| 归属于少数股东的综合收益总额 | -2,057,096.98 | -1,297,192.07 | -565,359.92 | -1,757,765.44 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |